GSK announces depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 17:00 Hrs [IS ...

London: GSK plc has announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorisation ...

EMA accepts for review GSK’s MAA for depemokimab for use in asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 09:00 Hrs [IST] GSK plc announced ...

GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.31 billion and an impressive gross profit margin of 72.39%, has announced that its new drug applications ...

Varner was only able to stay on the medication using Social Security disability support. She said if she didn’t have ...

If these trials confirm the findings, benralizumab could become the first new therapy approved for eosinophilic exacerbations ...

Obtained Class 1 Innovative Drug Long-acting Anti-IL-4Ra Monoclonal Antibody MG-K10 . SHENZHEN, CHINA, Jan 24, 2025 - (ACN News ...

China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on 24 January ...

R.F.K. Jr. and others have blamed the ingredient for allergies and other illnesses. Scientists say it actually bolsters the ...

She advises against touching, rubbing, or massaging the treated area for about 24 hours and to avoid working for about 48 hours post-injection. While most will start to notice the appearance of ...

Researchers explored a unique group of immune cells in the airways of people with severe asthma. The cells, called c-kit+IL-17A+ ILC2s, can be likened to chameleons; they can change their ...